ArticleAnnals of surgical oncology2026

Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era.

Maximilian Filzmayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.